Crosstalk of Splicing and Signaling during HSC Formation
Project Abstract
Cell fate specification depends on gene expression, which is the culmination of coordinated transcription, RNA
splicing, and translation. Although transcriptional regulation of cell fate choice is well-studied, the regulatory
role of RNA splicing in this process is poorly understood. Indeed, as RNA splicing is mostly studied in yeast
and cell culture, tissue-specific regulation of splicing in vivo is largely unexplored. Here, using hematopoietic
stem cell (HSC) formation as a paradigm for cell fate specification, we seek to illuminate how the molecular
regulation of RNA splicing impacts cell fate. During embryogenesis, a subset of blood-forming (i.e.
`hemogenic') endothelial cells undergoes a major cell fate transition from an `endothelial' identity to a nascent
HSC. Understanding this transition is critical for advancing both HSC-based regenerative medicine and our
basic understanding of blood genesis. We recently reported a severe HSC formation defect in zebrafish loss-
of-function mutants for the spliceosomal component, splicing factor 3b, subunit 1 (sf3b1). Surprisingly, we
found that this presumed constitutive splicing factor selectively regulates the fate of hemogenic endothelium
while leaving the identity of closely-related non-hemogenic endothelium unperturbed. Our central premise is
that splice isoform selection is a highly coordinated process critical for HSC formation. We hypothesize that the
splicing factor Sf3b1 is central to this coordination via directing splice isoform choice of signaling pathway
components essential for HSC formation, and that in turn these signaling pathways regulate Sf3b1-mediated
splicing outcomes. In this proposal, we will use zebrafish genetic and screening capabilities to address two
aims: (1) to determine how splicing impacts HSC fate choices by exploring the role of specific splice isoforms
on HSC formation and defining the function of cis-regulatory elements on Sf3b1-regulated splicing choices,
and (2) to determine signaling pathways impacting HSC splicing outcomes using chemical screening and
genomics approaches. Accomplishing these aims will inform our fundamental understanding of the poorly
understood role of splicing in hematopoietic lineage fate choice.